LI-RADS CT/MRI Treatment Response Assessment Update in 2024
The liver imaging reporting and data system (LI-RADS) CT/MRI treatment response assessment (TRA) provides a standardized framework for evaluating treatment response following loco-regional therapy for hepatocellular carcinoma (HCC). Initially introduced in 2017, it was revised in 2024 to reflect...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
The Korean Society of Radiology
2025-05-01
|
| Series: | Journal of the Korean Society of Radiology |
| Subjects: | |
| Online Access: | https://doi.org/10.3348/jksr.2025.0028 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | The liver imaging reporting and data system (LI-RADS) CT/MRI treatment response assessment
(TRA) provides a standardized framework for evaluating treatment response following
loco-regional therapy for hepatocellular carcinoma (HCC). Initially introduced in 2017, it
was revised in 2024 to reflect advances in research. The updated LI-RADS CT/MRI TRA v2024
presents a bifurcated algorithm based on the mechanisms underlying loco-regional therapy
and introduces distinct assessment criteria with which to evaluate treatment response
after radiation therapy. Furthermore, ancillary imaging features, including diffusion restriction
and mild-to-moderate T2 hyperintensity, have been incorporated as optional adjuncts
to refine the assessment of viable tumors. The effective implementation of the LI-RADS CT/
MRI TRA v2024 is anticipated to enhance treatment response assessment following loco-regional
therapy for HCC. Further research is encouraged in order to ensure the continuous
refinement and optimization of the assessment criteria. |
|---|---|
| ISSN: | 2951-0805 |